PortfoliosLab logo
NeoGenomics, Inc. (NEO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US64049M2098

CUSIP

64049M209

IPO Date

Nov 2, 1999

Highlights

Market Cap

$951.09M

EPS (TTM)

-$0.60

PEG Ratio

3.02

Total Revenue (TTM)

$672.36M

Gross Profit (TTM)

$294.43M

EBITDA (TTM)

-$93.00K

Year Range

$6.08 - $19.12

Target Price

$11.14

Short %

6.74%

Short Ratio

2.16

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


NeoGenomics, Inc.

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

NeoGenomics, Inc. (NEO) returned -55.83% year-to-date (YTD) and -48.00% over the past 12 months. Over the past 10 years, NEO returned 2.66% annually, underperforming the S&P 500 benchmark at 10.85%.


NEO

YTD

-55.83%

1M

13.84%

6M

-58.94%

1Y

-48.00%

3Y*

-4.73%

5Y*

-22.88%

10Y*

2.66%

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of NEO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-13.23%-30.14%-5.01%-32.61%13.84%-55.83%
2024-8.22%5.05%0.77%-11.45%-1.51%1.17%27.83%-6.82%-10.71%-7.86%30.46%-7.05%1.85%
202328.57%41.84%3.32%-16.03%17.51%-6.46%7.84%-13.27%-18.16%13.98%29.60%-10.95%75.11%
2022-33.94%-5.01%-43.25%-22.22%-10.90%-3.21%24.17%-0.69%-14.33%-11.67%47.40%-17.57%-72.92%
2021-1.52%-3.87%-5.38%1.58%-16.25%10.09%2.06%5.47%-0.78%-4.64%-25.52%-0.41%-36.63%
202010.19%-12.10%-2.54%-0.98%-2.38%16.07%23.40%1.88%-5.29%6.34%21.28%13.16%84.07%
201931.80%17.93%4.39%1.81%4.22%1.06%11.08%2.50%-23.46%19.93%12.56%13.33%131.96%
2018-12.87%8.81%-2.86%17.40%21.09%13.02%6.79%-1.07%10.83%20.13%-11.06%-23.11%42.33%
2017-5.95%0.12%-2.23%-4.31%0.13%18.52%5.47%6.98%10.09%-22.10%6.57%-4.11%3.38%
2016-13.34%-6.60%5.81%20.77%10.20%-10.37%8.46%-7.80%2.24%-1.95%10.92%-4.14%8.89%
2015-3.36%12.66%2.86%-3.00%17.66%1.50%12.94%-0.49%-5.76%23.04%13.05%-1.25%88.73%
201410.50%-10.50%-3.07%-4.61%2.42%-2.06%56.02%2.90%-2.25%8.45%-24.96%-1.65%15.19%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of NEO is 14, meaning it’s performing worse than 86% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of NEO is 1414
Overall Rank
The Sharpe Ratio Rank of NEO is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of NEO is 1818
Sortino Ratio Rank
The Omega Ratio Rank of NEO is 1616
Omega Ratio Rank
The Calmar Ratio Rank of NEO is 1818
Calmar Ratio Rank
The Martin Ratio Rank of NEO is 33
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for NeoGenomics, Inc. (NEO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

NeoGenomics, Inc. Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: -0.66
  • 5-Year: -0.34
  • 10-Year: 0.05
  • All Time: -0.02

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of NeoGenomics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


NeoGenomics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the NeoGenomics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NeoGenomics, Inc. was 99.98%, occurring on Apr 16, 2003. The portfolio has not yet recovered.

The current NeoGenomics, Inc. drawdown is 95.84%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.98%Dec 6, 1999826Apr 16, 2003
-44.44%Nov 11, 19991Nov 11, 19992Nov 16, 19993
-23.81%Nov 23, 19993Nov 26, 19991Nov 29, 19994
-6.25%Nov 18, 19991Nov 18, 19991Nov 19, 19992
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of NeoGenomics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of NeoGenomics, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -3,970.0%.


-0.20-0.100.000.1020212022202320242025
-0.20
-0.01
Actual
Estimate

Valuation

The Valuation section provides an overview of how NeoGenomics, Inc. is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for NEO compared to other companies in the Diagnostics & Research industry. NEO currently has a PEG ratio of 3.0. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for NEO relative to other companies in the Diagnostics & Research industry. Currently, NEO has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for NEO in comparison with other companies in the Diagnostics & Research industry. Currently, NEO has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items